Evidence map›Paper›PMID 39764277›Full record

ArticleJournal of clinical & translational endocrinology2024

The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC).

Dario de Biase, Andrea Repaci, Maria Concetta Nigro, Thais Maloberti, Francesca Carosi, Maria A Pantaleo, Giovanni Tallini, Margherita Nannini

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical & translational endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dario de BiaseSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.
Andrea RepaciDivision of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Maria Concetta NigroDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
Thais MalobertiSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.
Francesca CarosiDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
Maria A PantaleoDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
Giovanni TalliniSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.
Margherita NanniniDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as

Indexed as

Differentiated thyroid cancersRadioactive iodine refractoryTumor genotyping

Identifiers

PMID39764277
PMCPMC11701989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.